Can Stress-Blockers help fight melanoma? early trial launches
NCT ID NCT05968690
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests whether adding two stress-blocking drugs—naltrexone and propranolol—to standard immunotherapy (ipilimumab and nivolumab) is safe for people with advanced melanoma. The study aims to find the best dose and check for side effects in 12 participants. If successful, it may lead to larger studies exploring a new way to improve cancer treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
naltrexone and propranolol
What this could lead to
If this combination is safe, it could point toward a new way to boost the immune system's fight against advanced melanoma by blocking stress signals.
What could go wrong
This is a very early phase 1 trial with only 12 people, so it's mainly checking safety, not effectiveness. The added drugs may cause side effects or not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rutgers Cancer Institute of New Jersey
RECRUITINGNew Brunswick, New Jersey, 08903, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••